The Role of Circadian Biology in Health and Disease¶
Chapter 498 | Part 20: Emerging Topics in Clinical Medicine · Parts 19-20 – Consultative & Emerging Topics · Chapter 498
Key Clinical Points¶
- The suprachiasmatic nucleus (SCN) is the master pacemaker, entrained by light via melanopsin-expressing retinal ganglion cells.
- Circadian rhythms are generated by a transcription-translation autoregulatory feedback loop involving CLOCK/BMAL1 (activators) and PER/CRY (repressors).
- Delayed Sleep Phase Disorder (DSPD) affects 0.2–16% of the population, primarily in adolescence and early adulthood.
- Advanced Sleep Phase Disorder (ASPD) typically affects older individuals and may be underreported due to less social conflict.
- Non-24-h Sleep-Wake Rhythm Disorder occurs predominantly in individuals who are completely blind.
- Shift Work Sleep Disorder (SWSD) is linked to increased risks of metabolic, cardiovascular, and inflammatory diseases.
- Melatonin production is regulated by the SCN via a pathway involving the paraventricular nucleus of the hypothalamus (PVH).
- Circadian desynchrony—caused by shift work, jet lag, or genetic mutations—leads to multi-organ pathologies including obesity, hypertension, and impaired cognition.
- Genetic variants in PER3, CLOCK, and CRY1 are associated with diurnal preference and circadian sleep disorders.
- Treatment for DSPD involves a combination of morning bright-light therapy and evening melatonin administration.
DEFINITION & OVERVIEW¶
• Circadian Rhythms: Anticipatory, circa 24-h, autonomous cycles of physiology and behavior. ◦ Evolutionarily conserved at cell and tissue levels. ◦ Function: Enable organisms to anticipate rather than just react to daily environmental changes. • Master Pacemaker: Suprachiasmatic Nucleus (SCN) ◦ Located in the anterior hypothalamus. ◦ Entrained by light via melanopsin-expressing retinal ganglion cells. • Molecular Mechanism: Transcription-translation autoregulatory feedback loop. ◦ Forward limb: CLOCK and BMAL1 (or NPAS2) act as transcription factors. ◦ Negative limb: PERs and CRYs act as repressors. ◦ Secondary loop: ROR and REV-ERB regulate Bmal1 transcription. ◦ Post-translational regulation: Phosphorylation by CK1\epsilon and CK1δ; ubiquitination by FBXL3 and FBXL21. • Table 498-1 (Glossary): Key terms include: ◦ ASPD: Advanced sleep phase disorder. ◦ CCGs: Clock-controlled genes; output of the molecular clock. ◦ Circadian period: Time for one complete cycle (distance between two peaks/troughs). ◦ Constant routine: Experimental paradigm using dim light, isocaloric intake, and semirecumbent posture to study endogenous rhythms.
EPIDEMIOLOGY¶
• Delayed Sleep Phase Disorder (DSPD): Prevalence: 0.2–16% of the population. ◦ Most common in adolescence and early adulthood. • Advanced Sleep Phase Disorder (ASPD): Prevalence: <1% (potentially underreported). ◦ More common in older individuals. • Non-24-h Sleep-Wake Rhythm Disorder: Highest prevalence in individuals who are completely blind. • Shift Work Sleep Disorder (SWSD): Increasingly prevalent due to 24/7 society. ◦ Associated with increased risk of obesity, type 2 diabetes, cardiovascular disease, and cancer. • Chronotypes & Social Jetlag: Approximately 1% go to bed before 10:00 p.m.; 8% after 3:00 a.m. ◦ Melatonin peaks can vary by up to 4 h between extreme chronotypes. ◦ Chronic social jetlag is linked to increased risk of obesity, metabolic syndrome, and higher alcohol consumption/smoking. • Genetics: Up to 50% of the variation in diurnal preference is heritable.
ETIOLOGY & PATHOPHYSIOLOGY¶
• Circadian Rhythm Sleep Disorders (CRSDs): Defined as maladjustment of the biological clock with respect to the environment. ◦ Causes: Misalignment of exogenous factors (light) or activity-rest cycles (shift work/jetlag). • Anatomic Organization: SCN coordinates systemic physiology. ◦ Retino-hypothalamic tract (RHT): Carries signals from melanopsin-expressing neurons in the retina to the SCN. ◦ SCN Core: Contains VIP-producing neurons; receives direct photic input via RHT. ◦ SCN Shell: Contains AVP-producing neurons; synchronized by GABA release from the core. ◦ Downstream Pathways: SCN → MPO, SPZ, DMH, PVH, and PVT. ◦ Sleep Promotion: SCN signals to the ventrolateral preoptic nucleus (VLPO). ◦ Wake Promotion: SCN signals via SPZ and DMH to the locus coeruleus, lateral hypothalamic nucleus, ventral tegmental area, and dorsal raphe nucleus. ◦ Melatonin Regulation: SCN → PVH → Pineal gland (regulates melatonin production). • Table 498-3 (Animal Models): Key findings include: ◦ Bmal1-/-: Arrhythmic; no rhythm in SCN or periphery. ◦ Clock-/-: 0.5-h shorter period. ◦ Cry1-/-: 0.7-h shorter period. ◦ Cry2-/-: 1-h longer period. ◦ Dbp-/-: 0.5-h shorter period. ◦ Per1-/-: 0.7-h shorter period. ◦ Per2-/-: 1.5-h shorter period/arrhythmic. ◦ Per3-/-: 0 to 0.5-h shorter period. ◦ Rorα-//: Arrhythmic/various; impaired photic entrainment. ◦ Rorγ-//: Normal behavior.
CLINICAL FEATURES¶
• Delayed Sleep Phase Disorder (DSPD): Characterized by chronic, significant delays in sleep onset and wake times. ◦ Phenotype: "Extreme night owls." ◦ Associated with: Longer circadian period ( au), mutations in CLOCK, PER3, and CRY1. • Advanced Sleep Phase Disorder (ASPD): Characterized by advanced sleep episodes relative to desired times. ◦ Phenotype: "Extreme early birds;" early evening bedtimes/morning awakenings. ◦ Associated with: Mutations in PER2 or CK1δ (e.g., FAM-associated variants). • Non-24-h Sleep-Wake Rhythm Disorder: Characterized by 1–2 hour daily delays in sleep onset and wake times. ◦ Common in: Individuals with complete blindness. • Shift Work Sleep Disorder (SWSD): Insomnia or excessive sleepiness due to work during regular sleeping hours. • Irregular Sleep-Wake Rhythm (ISWR): Disrupted sleep-wake patterns without a clear phase shift. • Table 498-2 (CRSD Criteria): Criteria for CRSD include: 1. Persistent/recurrent pattern of sleep disturbance due to altered internal clock or misalignment with exogenous factors. 2. Associated impairment of social, occupational, or other areas of functioning."
DIFFERENTIAL DIAGNOSIS¶
• Distinguishing CRSDs: Based on the timing of the shift relative to the environment. ◦ DSPD: Shifted later (delayed). ◦ ASPD: Shifted earlier (advanced). ◦ Non-24-h: No entrainment (no 24-h cycle). ◦ SWSD: Induced by work schedule misalignment. • Genetic Markers (Table 498-4): Specific mutations linked to phenotypes: ◦ hCKI\epsilon (S408N, T44A) → Protection against DSPS. ◦ hCKI\Delta (H46R, T3111C) → FASPS. ◦ hCRY2 (A260T, S662G) → FASPS. ◦ hPER2 (C111G, P415A/H417R) → Extreme morningness. ◦ hPER3 (G647, etc.) → Morningness or DSPS.
MANAGEMENT & TREATMENT¶
- Delayed Sleep Phase Disorder (DSPD): Goal: Realign endogenous rhythm with social schedule. • Step 1: Bright-light therapy administered immediately after waking in the morning. • Step 2: Melatonin administration in the evening, several hours prior to intended sleep onset.
- Advanced Sleep Phase Disorder (ASPD): Goal: Delay the advanced sleep phase. • Strategy: Adjust light exposure and melatonin timing to shift the phase later.
- Non-24-h Sleep-Wake Rhythm Disorder: Goal: Establish a 24-h cycle. • Intervention: Bright-light therapy (if vision allows) or environmental cues to establish a stable period.
- Shift Work Sleep Disorder (SWSD): Goal: Mitigate consequences of shift work. • Strategy: Strategic use of light/dark environments and melatonin to manage sleep debt and phase alignment.
COMPLICATIONS & PROGNOSIS¶
• Metabolic and Cardiovascular Risks: Consequences of Circadian Desynchrony. ◦ Obesity, metabolic syndrome, and insulin resistance. ◦ Hypertension and cardiovascular disease. ◦ Dyslipidemia and steatosis (liver). • Neurologic Impairment: Impact on CNS function. ◦ Cognitive decline. ◦ Depression. ◦ Altered memory consolidation. • Other Systemic Pathologies (Figure 4): Desynchrony leads to: ◦ Hypoinsulinemia (pancreas). ◦ Disrupted HPA axis. ◦ Autoimmunity. ◦ Steatorrhea and IBD flare (intestine). ◦ Circadian dysbiosis.
SPECIAL CONSIDERATIONS¶
• Blindness: High risk for Non-24-h Sleep-Wake Rhythm Disorder due to lack of light entrainment. • Aging: Increased prevalence of ASPD and higher susceptibility to shift work complications. • Shift Workers: Higher incidence of metabolic disorders, inflammation, and cardiovascular issues due to chronic desynchrony.
KEY PEARLS & CLINICAL TRAPS¶
• Master Clock: SCN is the primary pacemaker; it uses VIP (core) and AVP (shell) to coordinate internal signals. • Melatonin Role: Melatonin has receptors in the SCN (MT1, MT2); it acts as both a signal and a feedback mechanism. • Circadian Period ( au): Mutations in PER2 can shorten au; mutations in PER3 can lead to DSPS or morningness. • Desynchrony: Circadian disruption is not just a sleep issue; it causes systemic issues like IBD flares, steatorrhea, and impaired glucose homeostasis.
Reference Tables¶
TABLE 498-1 Glossary of Terms Used in Discussion of the Circadian System¶
Harrison's 22e, p.3944
| TERM | DESCRIPTION |
|---|---|
| ASPD | Advanced sleep phase disorder (see text for description). |
| CCGs | Clock-controlled genes; output of the molecular clock. |
| Circadian period | Time required for one complete cycle or oscillation. Calculated by the time distance between two consecutive peaks or troughs of a circadian variable. |
| Circadian rhythm | A biological process that exhibits an endogenous, entrainable oscillation of ~24 h. |
| Constant routine | An experimental paradigm designed to study endogenous circadian rhythms in humans, by keeping behavioral and environmental factors constant. These paradigms thereby typically entail a combination of constant dim lighting, evenly distributed isocaloric energy intake, semirecumbent posture, and forced extended wakefulness. |
| Diurnal rhythm | An oscillation synchronized with the day/night cycle that repeats itself with a 24-h period. The rhythm does not have to persist when time cues (e.g., light) are absent. |
| DSPD | Delayed sleep phase disorder (see text for description). |
| Infradian rhythm | A recurrent cycle or period with a period length significantly greater than 24 h. |
| Non-24-h rhythm disorder | A syndrome in which there typically are chronic 1- to 2-h daily delays in sleep onset and wake times in an individual living in society, e.g., due to complete blindness. |
| PRC | Phase response curve; visual representation of how a particular manipulation (e.g., light) produces phase shifts as a function of the phase (i.e., circadian time) at which the manipulation occurs. Defining the PRC to light has enabled researchers to understand and predict how entrainment to light cycles is accomplished. |
| Shift work | Work scheduled so that it occurs outside of the traditional work schedule of 9:00 a.m. to 5:00 p.m., or 7:00 a.m. to 6:00 p.m., depending on definition. Various forms of shift work exist, such as early morning, evening, or night shifts, as well as rotating shifts. |
| P PERs |
|
| P CRYs |
|
| MAL1 | CLOCK |
| E-box |
TABLE 498-2 Criteria for Circadian Rhythm Sleep Disorders¶
Harrison's 22e, p.3947
| CRITERIA | DESCRIPTION |
|---|---|
| A | A persistent or recurrent pattern of sleep disturbance due primarily to one of the following: • Alterations of the internal circadian timekeeping system. • Misalignment between endogenous circadian rhythms and exogenous factors that affect the timing or duration of sleep. |
| C | A sleep disturbance that is associated with impairment of social, occupational, or other areas of functioning. |
TABLE 498-3 Animal Models of Genetic Circadian Disruption GENE Bmal1 (Arntl) CK1 δ (Csnk1 δ ) CK1 ε (Csnk1 ε ) CK1 ε…¶
Harrison's 22e, p.3947
| GENE | AVERAGE CIRCADIAN TIME OF PEAK TRANSCRIPT LEVEL | ALLELE | MUTANT PHENOTYPE | |
|---|---|---|---|---|
| SCN | PERIPHERY | |||
| Bmal1 (Arntl) | 15–21 | 22–2 | Bmal1−/− | Arrhythmic |
| No rhythm | No rhythm | Csnk1δ+/– | ||
| CK1ε (Csnk1ε) | No rhythm | No rhythm | CK1εtau | 4-h shorter period |
| — | — | CK1ε−/− | ||
| Clock | No rhythm | 21–3 | Clock−/− | 0.5-h shorter period |
| — | — | ClockD19/D19 | ||
| Clock/Npas2 | — | — | Clock−/−/NPAS2−/− | Arrhythmic |
| 8–14 | 14–18 | Cry1−/− | ||
| Cry2 | 8–14 | 8–12 | Cry2−/− | 1-h longer period |
| — | — | Cry2A260T | ||
| Dbp | — | — | Dbp−/− | 0.5-h shorter period |
| N/A | 0–4 | Npas2−/− | ||
| Per1 | 4–8 | 10–16 | Per1−/− | 0.7-h shorter period |
| — | — | — | Per1brdm1 | 1-h shorter period |
| — | — | Per1ldc | ||
| Per2 | 6–12 | 14–18 | Per2brdm1 | 1.5-h shorter period/arrhythmic |
| — | — | Per2ldc | ||
| Per3 | 4–9 | 10–14 | Per3−/− | 0 to 0.5-h shorter period |
| 2–6 | 4–10 | Rev-erbα−/− | ||
| Rorα | 6–10 | Arrhythmic/various | staggerer | 0.5-h shorter period/disrupted photic entrainment |
| 4–8 | 18–22 | Rorβ−/− | ||
| Rorγ | N/A | 16–20/various | Rorγ−/− | Normal behavior |
TABLE 498-4 Mutations and Gene Variants Linked to Sleep-Wake Disorders and Diurnal Preference GENE h CKI ε h CKI γ h…¶
Harrison's 22e, p.3948
| GENE | POSITION | POPULATION | SYNDROME/SLEEP PREFERENCE |
|---|---|---|---|
| hCKIε | S408N | Japanese | Protection against DSPS |
| T44A | Pedigree | ||
| hCKIΔ | H46R | Pedigree | FASPS |
| T3111C (3′-UTR) | European | ||
| hCRY2 | A260T | Pedigree | FASPS |
| S662G (missense mutations in CKIε binding region) | Pedigree | ||
| hPER2 | C111G (5′-UTR) | British | Extreme morningness |
| P415A/H417R | Pedigree | ||
| hPER3 | G647 | Swedish/Finish/Austrian/German | Morningness |
| G647, P864, 4-repeat, T1037, R1158 | Japanese | ||
| hPER3 | Increased repeats (exon 18, 54 bp) | Brazilian | DSPS |
| rs9479402 (gene variant 54 kb upstream of VIP) | European (>97% European ancestry) |